Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6254182 | 0.84 | MTTP (0.58) | F2F10PRSS1L3MBTL1ALDH1A1 | |
| SCHEMBL6225121 | 0.81 | F2 (0.53) | F2F10PRSS1 | |
| SCHEMBL6259960 | 0.81 | NPC1 (0.47) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL6223809 | 0.79 | F2 (0.51) | F2F10PRSS1 | |
| SCHEMBL6221944 | 0.78 | PRSS1 (0.54) | PRSS1 | |
| SCHEMBL6255765 | 0.76 | MTTP (0.58) | F2F10PRSS1L3MBTL1ALDH1A1 | |
| SCHEMBL6254177 | 0.74 | L3MBTL1 (0.45) | F2L3MBTL1ALDH1A1LMNA | |
| SCHEMBL5382862 | 0.74 | F2 (0.63) | F2F10PRSS1 | |
| SCHEMBL4793272 | 0.73 | KMT2A (0.56) | F2F10PRSS1 | |
| SCHEMBL12168556 | 0.71 | CA12 (0.61) | F2F10PRSS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132745-A1 | Microsomal triglyceride transfer protein inhibitor | PFIZER INC | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132745-A1 | Microsomal triglyceride transfer protein inhibitor | MTTP, CETP, APOB | F2 1647/4885F10 2014/4885PRSS1 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.